Comparative Pharmacology
Head-to-head clinical analysis: MODURETIC 5 50 versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODURETIC 5 50 versus ZIAC.
MODURETIC 5-50 vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination diuretic: amiloride blocks epithelial sodium channels (ENaC) in distal tubule, inhibiting sodium reabsorption and potassium excretion; hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
1 tablet (5 mg amiloride/50 mg hydrochlorothiazide) orally once daily, increased if needed to 2 tablets daily as a single dose or divided doses.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
HCTZ: 5.6-14.8 hours; amiloride: 6-9 hours. Both prolonged in renal impairment (e.g., creatinine clearance <30 mL/min). Terminal elimination half-life for HCTZ may extend to >20 hours in severe renal disease.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Both components are primarily excreted renally: hydrochlorothiazide (HCTZ) ~70% unchanged in urine; amiloride ~50% unchanged in urine. Minor biliary/fecal elimination (<10% for each).
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Diuretic
Beta Blocker + Diuretic